SCHEDULE 13G: Investment Group Led by Matthew Smith Discloses Significant Stake in Precision BioSciences

A group of investment entities and individuals, including Readout Capital and Matthew Smith, have disclosed beneficial ownership of up to 8.9% of Precision BioSciences Inc.'s common stock.

Summary

• A Schedule 13G filing by Readout Capital, LP, Readout Capital GP, LLC, ROC Holdings SPV II, LP, Readout Holdings GP, LLC, and Matthew Smith (collectively, the "Reporting Persons") discloses their beneficial ownership in Precision BioSciences Inc.
• Matthew Smith, the Manager of Readout Holdings GP and Readout Capital GP, is reported to beneficially own the largest stake among the group, totaling 932,874 shares, which represents 8.9% of Precision BioSciences Inc.'s common stock.
• Readout Capital, LP and Readout Capital GP, LLC each beneficially own 920,000 shares, equating to 8.8% of the outstanding common stock.
• ROC Holdings SPV II, LP and Readout Holdings GP, LLC each beneficially own 720,000 shares, representing 6.9% of the outstanding common stock.
• These ownership percentages are calculated based on 10,481,931 shares of Precision BioSciences Inc. common stock outstanding as of March 20, 2025.
• The Reporting Persons have certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory filing.

Positives

• The disclosure of a significant beneficial ownership stake by an investment group may signal confidence in Precision BioSciences Inc.'s long-term value proposition.
• The stated passive investment intent, not seeking to influence control (with the exception of potential Rule 14a-11 nominations), can be viewed as a stable form of institutional investment.

Negatives

• This regulatory filing does not contain any information that would be considered negative regarding Precision BioSciences Inc.'s operations or financial performance.

Risks

• The Schedule 13G filing is solely for ownership disclosure and does not detail specific operational, financial, or strategic risks pertaining to Precision BioSciences Inc.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Industry Context

This filing indicates a significant passive investment in Precision BioSciences, a biotechnology company. While the filing itself does not provide industry-specific trends, the accumulation of a notable stake by an investment group suggests a potential belief in the long-term value or strategic positioning of the company within the broader biotechnology sector, particularly in areas related to its common stock.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure of beneficial ownership, which is a common regulatory requirement for investors acquiring more than 5% of a company's stock.
• It does not provide information for direct comparison to specific comparable companies, projects, or results within the biotechnology industry, as its focus is solely on the ownership structure of Precision BioSciences Inc. by the reporting entities.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment group could influence investor perception and potentially stock liquidity.
• Management: The passive nature of the investment (not seeking control) generally indicates no immediate threat to current management, though the ability to nominate under Rule 14a-11 is noted.

Next Steps

• The document does not outline any specific future actions, events, or milestones for Precision BioSciences Inc. or the reporting persons beyond the regulatory filing itself.

Key Dates

Keywords

Precision BioSciences Inc., Beneficial Ownership, Schedule 13G, Common Stock, Readout Capital, Matthew Smith, SEC Filing, Institutional Investor, Equity Stake